Control of the solid form of a lead drug candidate through scale-up to clinic and commercial manufacture is essential for multiple reasons, including safety, efficacy and also IP. X-ray diffraction (XRD) is the gold standard technique for the assessment of a compound’s solid form and stability. Benchtop XRD systems enable greater access to this key technology, but in comparison to floor-standing XRD systems there is often a compromise on capability. Most notably, floor-standing systems are capable of transmission XRD, where greater peak resolution and accuracy affords improved identification and quantification of the solid form and its polymorphs.
The Aeris X-ray diffractometer is a game-changer, because it brings transmission XRD capability to the benchtop. This enables greater control of an API’s solid form throughout preclinical development and through into QC labs.
In this webinar, we will compare reflection and transmission configurations of XRD with reference to various drug development processes. We will also discuss the benefits of greater access to this capability to scientists at the lab bench.
- Dr. Martin Schreyer - Application Specialist XRD - Malvern Panalytical
Who should attend?
- Anyone interested in solid-state analysis
- Anyone using XRD in development or QA/QC settings
- Anyone who is interested in benchtop systems
What will you learn?
- Improve your understanding of solid-state analysis and the XRD technique
- Compare the different configurations of XRD reflection and transmission modes
- Consider the benefits of improved and simplified access to greater analytical capability